RESIST pursues research for people whose immune system is not strong enough for the defence against pathogens. These are, for example, newborns, seniors, people with a congenital immune deficiency and people whose immune system is attenuated for therapeutic reasons or who have been transplanted with an organ or stem cells.<\/p>\n
RESIST scientists investigate pathogenic viruses and bacteria as well as the human defence mechanisms \u2013 and especially how both of them interact with each other. Our approach involves clinical and patient cohort studies as the basis for basic research.<\/p>\n
We are pleased that RESIST is so international: many people in our RESIST team come from abroad and \/ or work with colleagues in institutions around the world, and many (post)doctoral students have also joined us from abroad. Read more about this on our\u00a0<\/a>page “I<\/a>nternationalisation”.<\/a><\/p>\n<\/div><\/div><\/i><\/span>\nThe scientific questions of our individual projects<\/a><\/p>\n<\/div><\/li><\/ul><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Four project areas \u2013 one goal<\/h1><\/div><\/div><\/div><\/a><\/span><\/div><\/div><\/div>RESIST research is organised in four project areas:<\/p>\nArea A comprises all projects that deal with genetic factors: The role of human genes and gene variants for susceptibility to infections is investigated. Area B is all about the human immune system and why some people are particularly susceptible to infections with viruses and bacteria, for example newborns and elderly individuals. In areas C and D, pathogenic bacteria and viruses respectively are analysed: How do they \u201csettle\u201d permanently in the body and cause chronic infections \u2013 for example in the lungs, liver and on implants?<\/p>\nPatients are at the centre of all efforts: The common goal of all research areas is a better protection of vulnerable people by better prediction of the course of an infection or by improved diagnostic and therapeutic options.<\/p>\n<\/div><\/div>Learn more about RESIST<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>The scientific questions of our individual projects<\/h1><\/div><\/div><\/div>Project area A (Genes)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>A1<\/strong> | Severe lung infections – Which genetic factors make some children particularly susceptible?<\/a><\/p>\nA2<\/strong> | Congenital immunodeficiency – How can diagnosis be improved to achieve early identification of as many affected individuals as possible?<\/a><\/p>\nA3<\/strong> | Varicella-Zoster – Which genetic factors lead to severe disease progressions? <\/a><\/p>\nA4<\/strong> | Herpes infections – Which mechanisms lead to severe disease progression in humans with atopic dermatitis?\n<\/a><\/p>\nA5<\/strong> | What genetic changes predispose people to infections?<\/a><\/p>\nA6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
The scientific questions of our individual projects<\/a><\/p>\n<\/div><\/li><\/ul><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Four project areas \u2013 one goal<\/h1><\/div><\/div><\/div><\/a><\/span><\/div><\/div><\/div>RESIST research is organised in four project areas:<\/p>\nArea A comprises all projects that deal with genetic factors: The role of human genes and gene variants for susceptibility to infections is investigated. Area B is all about the human immune system and why some people are particularly susceptible to infections with viruses and bacteria, for example newborns and elderly individuals. In areas C and D, pathogenic bacteria and viruses respectively are analysed: How do they \u201csettle\u201d permanently in the body and cause chronic infections \u2013 for example in the lungs, liver and on implants?<\/p>\nPatients are at the centre of all efforts: The common goal of all research areas is a better protection of vulnerable people by better prediction of the course of an infection or by improved diagnostic and therapeutic options.<\/p>\n<\/div><\/div>Learn more about RESIST<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>The scientific questions of our individual projects<\/h1><\/div><\/div><\/div>Project area A (Genes)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>A1<\/strong> | Severe lung infections – Which genetic factors make some children particularly susceptible?<\/a><\/p>\nA2<\/strong> | Congenital immunodeficiency – How can diagnosis be improved to achieve early identification of as many affected individuals as possible?<\/a><\/p>\nA3<\/strong> | Varicella-Zoster – Which genetic factors lead to severe disease progressions? <\/a><\/p>\nA4<\/strong> | Herpes infections – Which mechanisms lead to severe disease progression in humans with atopic dermatitis?\n<\/a><\/p>\nA5<\/strong> | What genetic changes predispose people to infections?<\/a><\/p>\nA6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
RESIST research is organised in four project areas:<\/p>\n
Area A comprises all projects that deal with genetic factors: The role of human genes and gene variants for susceptibility to infections is investigated. Area B is all about the human immune system and why some people are particularly susceptible to infections with viruses and bacteria, for example newborns and elderly individuals. In areas C and D, pathogenic bacteria and viruses respectively are analysed: How do they \u201csettle\u201d permanently in the body and cause chronic infections \u2013 for example in the lungs, liver and on implants?<\/p>\n
Patients are at the centre of all efforts: The common goal of all research areas is a better protection of vulnerable people by better prediction of the course of an infection or by improved diagnostic and therapeutic options.<\/p>\n<\/div>
A1<\/strong> | Severe lung infections – Which genetic factors make some children particularly susceptible?<\/a><\/p>\nA2<\/strong> | Congenital immunodeficiency – How can diagnosis be improved to achieve early identification of as many affected individuals as possible?<\/a><\/p>\nA3<\/strong> | Varicella-Zoster – Which genetic factors lead to severe disease progressions? <\/a><\/p>\nA4<\/strong> | Herpes infections – Which mechanisms lead to severe disease progression in humans with atopic dermatitis?\n<\/a><\/p>\nA5<\/strong> | What genetic changes predispose people to infections?<\/a><\/p>\nA6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
A2<\/strong> | Congenital immunodeficiency – How can diagnosis be improved to achieve early identification of as many affected individuals as possible?<\/a><\/p>\nA3<\/strong> | Varicella-Zoster – Which genetic factors lead to severe disease progressions? <\/a><\/p>\nA4<\/strong> | Herpes infections – Which mechanisms lead to severe disease progression in humans with atopic dermatitis?\n<\/a><\/p>\nA5<\/strong> | What genetic changes predispose people to infections?<\/a><\/p>\nA6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
A3<\/strong> | Varicella-Zoster – Which genetic factors lead to severe disease progressions? <\/a><\/p>\nA4<\/strong> | Herpes infections – Which mechanisms lead to severe disease progression in humans with atopic dermatitis?\n<\/a><\/p>\nA5<\/strong> | What genetic changes predispose people to infections?<\/a><\/p>\nA6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
A4<\/strong> | Herpes infections – Which mechanisms lead to severe disease progression in humans with atopic dermatitis?\n<\/a><\/p>\nA5<\/strong> | What genetic changes predispose people to infections?<\/a><\/p>\nA6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
A5<\/strong> | What genetic changes predispose people to infections?<\/a><\/p>\nA6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
A6<\/strong> | Is the human virome a potential factor of infection susceptibility?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area B (Immune system)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B1<\/strong> | Which influence do intestinal bacteria have on susceptibility to infection?<\/a><\/p>\nB2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B2<\/strong> | Can intestinal bacteria trigger rheumatological diseases?<\/a><\/p>\nB3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B3<\/strong> |\u00a0Which impact do intestinal bacteria and infections have on the fitness of immune cells?<\/a><\/p>\nB4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B4<\/strong>\u00a0|How can immune receptors be used for therapeutic puposes?<\/a><\/p>\nB5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B5<\/strong> | Do advanced age and allergies contribute to the reactivation of dormant herpes viruses?<\/a><\/p>\nB6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B6 <\/strong>Cytomegaloviruses persist permanently in the body and are a constant stimulant of the immune system. Does this make the course of atherosclerosis or diabetes worse?<\/a><\/p>\nB7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B7<\/strong> | Does age have an effect on immune responses against viruses?<\/a><\/p>\nB8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B8<\/strong> | Chronic hepatitis B: Why do some people recover spontaneously after therapy disruption?<\/a><\/p>\nB9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B9<\/strong> | Hepatitis B – What causes vaccine failure and which new therapies are possible?<\/a><\/p>\nB10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B10<\/strong> | Hepatitis C – Which immune response can contribute to the development of a new vaccine?<\/a><\/p>\nB11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B11<\/strong> | Cholangitis – Which individual therapy approaches are possible?<\/a><\/p>\nB12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B12<\/strong> | Can bacterial infections be treated with ubiquitins?<\/a><\/p>\nB13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B13<\/strong> | How can we fight lung infections?<\/a><\/p>\nB14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
B14<\/strong> | How does the hepatitis D Virus bypass the immune system?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area C (bacteria)<\/a><\/span><\/h2><\/div><\/div><\/div><\/div>C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
C1<\/strong> | Which new strategies are effective against biofilm-associated infections?<\/a><\/p>\nC2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
C2<\/strong> | Which individual human factors favour the formation of Biofilms?<\/a><\/p>\nC3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
C3<\/strong> | How can we affect bacterial communities in chronic lung diseases?<\/a><\/p>\nC4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
C4<\/strong> | What influence does genetic diversity have on the bacterial phenotype?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>Project area D (viruses)<\/a>\u00a0<\/span><\/h2><\/div><\/div><\/div><\/div>D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
D1<\/strong> |\u00a0 Herpesvirus: How can we stop the life cycle of persistent viral pathogens at an early stage?<\/a><\/p>\nD2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
D2<\/strong> | What new therapeutic options open up, from research into the assembly process of herpesviruses?<\/a><\/p>\nD3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
D3<\/strong> | Herpesvirus infections: How can novel drug targets be identified?<\/a><\/p>\nD4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
D4<\/strong> |\u00a0Can we use the modulation of the immunosensors OAS and cGAS for the development of new drugs against infectious and inflammatory diseases?<\/a><\/p>\nD5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
D5<\/strong> |\u00a0Which paths lead to new inhibitors against human adenoviruses?<\/a><\/p>\nD6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>
D6 <\/strong>|\u00a0 Why do infections with hanta- and arenaviruses progress so differently?<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/path><\/svg><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Understand infections \u2013 Interview with Prof. Schulz<\/h1><\/div>